400
Participants
Start Date
July 20, 2023
Primary Completion Date
December 30, 2024
Study Completion Date
July 20, 2026
Obinutuzumab
obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Changzhou No.2 People's Hospital, Changzhou
The First People's hospital of Changzhou, Changzhou
Huai'an First People's hospital, Huai'an
Jiangyin People's Hospital, Jiangyin
Jingjiang People's Hospital, Jingjiang
The first people's hospital of Lianyungang, Lianyungang
The second people's hospital of Lianyungang, Lianyungang
Jiangsu Province Hospital of Chinese Medicine, Nanjing
Jiangsu Province Hospital, Nanjing
Nanjing Drum Tower Hospital, Nanjing
Nanjing Jiangning Hospital, Nanjing
Nantong Tumor Hospital, Nantong
Affiliated Hospital of Nantong University, Nanyang
The Second Affiliated Hospital of Soochow University, Suzhou
Jiangsu Taizhou People's Hospital, Taizhou
Affiliated Hospital of Jiangnan University, Wuxi
Wuxi People's Hospital, Wuxi
Wuxi Second People's Hospital, Wuxi
Yancheng No.1 People's Hospital, Yancheng
Yancheng Third People's Hospital, Yancheng
Subei People's Hospital, Yangzhou
Yixing People's Hospital, Yixing
Zhangjiagang First People's Hospital, Zhangjiagang
Affiliated Hospital of Jiangsu University, Zhenjiang
Zhenjiang First People's Hospital, Zhenjiang
Affiliated Hospital of Nantong University
OTHER